Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021

Rhea-AI Summary

Exelixis, Inc. (Nasdaq: EXEL) announced that Dr. Peter Lamb, its Executive VP and Chief Scientific Officer, will present at the William Blair Biotech Focus Conference on July 15, 2021, at 2:00 p.m. EDT. Interested participants can access the webcast via www.exelixis.com and should connect 15 minutes early. A replay will be available for 14 days. Founded in 1994, Exelixis focuses on oncology and has developed four commercial products, including CABOMETYX and COMETRIQ, while also collaborating with leading pharmaceutical companies.

Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the company’s Executive Vice President, Scientific Strategy and Chief Scientific Officer, will present at the virtual William Blair Biotech Focus Conference 2021 on Thursday, July 15^th at 2:00 p.m. EDT / 1:00 p.m. CDT / 11:00 a.m. PDT.

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX^® (cabozantinib), COMETRIQ^® (cabozantinib), COTELLIC^® (cobimetinib) and MINNEBRO^® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune’s 100 Fastest-Growing Companies list for the first time, ranking 17^th overall and the third-highest biopharmaceutical company. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005288/en/

FAQ

When is the William Blair Biotech Focus Conference presentation by Exelixis?

Dr. Peter Lamb will present at the William Blair Biotech Focus Conference on July 15, 2021, at 2:00 p.m. EDT.

How can I access the Exelixis webcast of the conference?

You can access the Exelixis webcast at www.exelixis.com under the News & Events / Event Calendar section.

What products has Exelixis developed?

Exelixis has developed four commercial products, including CABOMETYX, COMETRIQ, COTELLIC, and MINNEBRO.

What is Exelixis's focus in biotechnology?

Exelixis focuses on developing new medicines for difficult-to-treat cancers.

Is there a replay available for the Exelixis presentation?

Yes, a replay of the Exelixis presentation will be available for 14 days on the company's website.